[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
To further evaluate the efficacy and side-effects of domastic amsacrine. Two handred and ninty-one patients with acute leukemias, including initial, relapsed and refractory cases, were treated with regimens combining the amsacrine with other antileukemic drugs. The total CR rate was 43.3% in ALL and 49.0% in ANLL. The CR rates of relapsed/refractory ALL and ANLL was 28.9% and 34.4%, respectively. The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens. The pharmacokinetic parameters of the domastic amsacrine, C12h/C6h, K21 were correlated with therapeutic effectiveness.